Second-line treatments in EGFR-mutated metastatic non-small-cell lung cancer (NSCLC) beyond osimertinib - Amsterdam 2025

Precision medicine in lung cancer, novel therapies and toxicity management

Chair(s): Daniela Xhemalaj, Amanda Tufman

Session type: Poster session

Second-line treatments in EGFR-mutated metastatic non-small-cell lung cancer (NSCLC) beyond osimertinib

Camille Mehlman

EVENTS HOME

Poster
Abstract

Previous presentation

Next presentation

Session content

Up-regulating methylation of CAP1 promoter can promote apoptosis and inhibit migration and invasion of lung adenocarcinoma cells

Yunlu Gu

Poster

Abstract

Multi-molecular markers in lung adenocarcinoma: Novel predictive value of NPC2, PLOD2, and ALCAM expression

Yuanjie Li

Poster

Abstract

Treatment patterns and outcomes in HER2-mutated non-small cell lung cancer: a retrospective analysis

Mariana Cascais

Poster

Abstract

Clinical and radiological characteristics of ROS1-Positive and ALK-Positive non-small cell lung cancer: a retrospective analysis

Mariana Cascais

Poster

Abstract

Impact of Immune Checkpoint Inhibitor-related Interstitial Lung Disease on Overall and Progression-Free Survival in Non-Small Cell Lung Cancer Patients Treated with Immunotherapy

Alice Carrette

Poster

Abstract

Comparison of BALF cellular pattern in immune checkpoint inhibitor-related pneumonitis versus radiation induced-pneumonitis (RP)

Dagmar Duesterhoeft

Poster

Abstract

Machine learning to support treatment modality selection in early-stage lung cancer

Fatemeh Farajpourlar

Poster

Abstract

Immune checkpoint inhibitor-related pneumonitis in lung cancer patients: a retrospective analysis of severity and outcomes

Giacomo Guglielmi

Poster

Abstract

Predictive factors for immune related interstitial lung disease and survival outcomes in lung cancer

Inês Maria Brito Gonçalves

Poster

Abstract

Interim Analysis of pulmonary tolerability from the multicenter ROSE Study: Radiation during Osimertinib Treatment Safety and Efficacy Cohort

Amanda Tufman

Poster

Abstract

Repotrectinib in ROS1 Fusion-Positive Non- Small-Cell Lung Cancer: A Systematic Review and Meta-Analysis

Mohammedbaqer Ghuraibawi

Abstract

Second-line treatments in EGFR-mutated metastatic non-small-cell lung cancer (NSCLC) beyond osimertinib

Camille Mehlman

Poster

Abstract

Human Lung Macrophages and Circulating Monocytes Might Contribute to Bacterial Infection Susceptibility and Prognosis of Lung Cancer Patients

Francesco Palestra

Abstract

Diagnosis, treatment and outcomes of ALK-positive NSCLC: real-world data analysis

Joana Catarina Neto Lourenço

Poster

Abstract

Real-World Cardiovascular Risk Comparison of First-Line Osimertinib and Earlier Generation EGFR-TKIs in EGFR-Mutated NSCLC: A TriNetX USA Network Analysis

Wen-chien Cheng

Poster

Abstract

Influence of emphysema on Tregs, lymphocytes, molecules CTLA-4 and PD-1 in patients with lung cancer and co-existence of COPD.

Robert Ulinski

Poster

Abstract

Sex-Specific Differences in Tumor Cell Number and Activation in Metastatic Lymph Nodes of Lung Cancer

Iwona Kwiecien

Poster

Abstract

Impact of subsequent treatment on clinical outcomes in patients with EGFR-mutant non-small cell lung cancer transformed to small-cell lung cancer

Yu-feng Wei

Poster

Abstract

Novel functionally conserved oncogene COA4 was driven by KRAS and involved in LUAD metastasis

Xingzhao Ji

Poster

Abstract

Nicotine dependence in patients with advanced-stage lung cancer

Chaima Habouria

Poster

Abstract

CDN Connection Issue

The ERS Congress 2025, Amsterdam

#{title}